Regarding the treatment of relapsed/refractory B-ALL, adoptive T cells expressing a CAR directed against the B-cell-associated surface marker, CD19, have been used in several clinical trials8–12. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.